CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 180 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2021. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $75,157 | -12.9% | 2,731 | +7.4% | 0.00% | 0.0% |
| Q2 2023 | $86,284 | -5.7% | 2,543 | 0.0% | 0.00% | -20.0% |
| Q1 2023 | $91,497 | -27.5% | 2,543 | -10.2% | 0.01% | -16.7% |
| Q4 2022 | $126,267 | +49.9% | 2,833 | -5.4% | 0.01% | +50.0% |
| Q3 2022 | $84,218 | +4.3% | 2,996 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $80,772 | -20.8% | 2,996 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $102,044 | -78.3% | 2,996 | -75.3% | 0.00% | -33.3% |
| Q4 2021 | $469,399 | -28.4% | 12,148 | 0.0% | 0.01% | -40.0% |
| Q3 2021 | $655,871 | +76.6% | 12,148 | +9.4% | 0.01% | +100.0% |
| Q2 2021 | $371,418 | – | 11,107 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |